Immunodiagnostic trims jobs as sales slump in the past year

Immunodiagnostic Systems' fully automated system for lab and clinic tests
Immunodiagnostic Systems' fully automated IDS-iSYS Multi- Discipline Automated System

British laboratory and clinic testing kit maker Immunodiagnostic Systems says slumping sales have cost 31 jobs at its Boldon manufacturing facility over the past 12 months.

In its full-year trading update, the company said full-year sales for the 12 months ended March 31 fell 13% to about £39 million ($57 million). The company, which makes both manual and automated testing kits, said the losses were mostly due to sluggish sales in its manual assay business where test volumes continue to move toward automated solutions where there is more competition, the Chronicle reported.

Immunodiagnostic reported a total of 315 employees on a full time basis, which is down 31 from a year ago.

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

The company has manufacturing facilities in Boldon and Italy, as well as an instrument production and system engineering in France and a manufacturing facility in Liege, Belgium.

The declines in sales are expected to last through this year.

- check out the Chronicle story

Related Articles:
Embark Veterinary launches DNA testing kit for dogs
European investor shells out $118M for DNA testing outfit to boost animal Dx offerings

Image courtesy of Immunodiagnostic Systems


Suggested Articles

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.

Pfizer is pushing back on a Thursday report claiming it suddenly revised its COVID-19 vaccine targets for 2020, saying it announced that last month.